JAKARTA, KOMPASTV – The existence of SARS-CoV2 vaccine is highly anticipated.
The Indonesian Institute of Sciences (LIPI) is pursuing the production of vaccines produced in Indonesia.
LIPI Deputy of Engineering, Agus Haryono said the results of clinical trials conducted at Biofarma Bandung were highly awaited, because it would show the potential for how Indonesia could independently produce vaccines.
Quoted from the LIPI webpage, noted that the LIPI Bio Safety Laboratory Level 3 (BSL-3) is currently a supporting facility for vaccine testing.
Also Read: UNPAD Leads Corona Vaccine Clinical Trial, Registration for 1,620 Volunteers Has Been Opened!
LIPI Biotechnology Research Center researcher Wien Kusharyoto explained that for the SARS-CoV2 vaccine, LIPI chose to develop a recombinant vaccine sub-unit, which means the vaccine was taken only from parts of the virus body, namely Protein Spike (Protein S).
Wien explained that the process of developing a vaccine so that it can be mass produced and used in humans with utmost safety takes a long time.